AsianScientist (May 29, 2018) – WuXi Biologics, a global biologics technology platform company listed in Hong Kong, plans to construct an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, the capital of Hebei province in northern China.
Its new biologics center in Shijiazhuang will include process development labs, a clinical manufacturing facility with 5,000 L bioreactor capacity and a commercial manufacturing facility with 48,000 L bioreactor capacity. These will be built to meet the current good manufacturing practice (cGMP) standards of the US, the European Union and China.
The new integrated center will also address the urgent needs of Chinese partners in the biomedical sector. The initial phase of the center will be operational in 2020.
“We are very pleased to establish the largest biologics center in northern China, which will enable local companies to more effectively develop and manufacture biologics, and in the meantime, provide a robust supply chain network for our global clients. This expansion will allow us great access to local talents, markets and government support,” said Dr. Chris Chen, chief executive officer of WuXi Biologics.
“With this investment and the 161 biologics programs that WuXi Biologics will manufacture, we will quickly and cost effectively expand our manufacturing capacity to meet our partners’ needs and become one of the global CMO leaders,” he added.
———
Source: WuXi Biologics; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
